CAS No. |
57576-44-0 |
中文名称 |
(1R,2R,4S)-4-(((2R,4S,5S,6S)-4-(二甲氨基)-5-(((2S,4S,5S,6S)-4-羟基-6-甲基-5-(((2R,6S)-6-甲基-5-氧代四氢-2H-吡喃-2-基)氧基)四氢-2H-吡喃-2-基)氧基)-6-甲基四氢-2H-吡喃-2-基)氧基)-2-乙基-2,5,7-三羟基-6,11-二氧代-1,2,3,4,6,11-六氢并四苯-1-羧酸甲酯 |
英文名称 |
methyl (1R,2R,4S)-4-(((2R,4S,5S,6S)-4-(dimethylamino)-5-(((2S,4S,5S,6S)-4-hydroxy-6-methyl-5-(((2R,6S)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate |
别名 |
1-naphthacenecarboxylicacid,2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6;aclacur;aclarubicinfreebase;antibiotic3082a;ACLARUBLCIN;ACLARUNBICIN;1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-, methyl ester, [1R-(1α,2β,4β)]-;Jaclacin |
标准英文名 |
methyl (1R,2R,4S)-4-(((2R,4S,5S,6S)-4-(dimethylamino)-5-(((2S,4S,5S,6S)-4-hydroxy-6-methyl-5-(((2R,6S)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate |
分子式 |
C42H53NO15 |
分子量 |
811.34
|
精确分子量 |
811.34
|
SMILES |
COC([C@@H]1C2=C(C(O)=C3C(C(C4=CC=CC(O)=C4C3=O)=O)=C2)[C@H](C[C@]1(O)CC)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@@H]7O[C@H](C(CC7)=O)C)O)N(C)C)=O |
标准SMILES |
COC(=O)[C@@H]1C2C=C3C(C(=O)C4C(=CC=CC=4O)C3=O)=C(O)C=2[C@H](C[C@]1(O)CC)O[C@H]1C[C@@H]([C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3CCC(=O)[C@H](C)O3)[C@H](C)O2)[C@H](C)O1)N(C)C |
用途 |
Aclarubicin is a second-generation anthracycline antitumor antibiotic and a cell cycle non-specific agent that inhibits the biosynthesis of DNA, RNA, and proteins. It exhibits potent anticancer activity and can be administered orally, with significantly lower cardiotoxicity compared to doxorubicin and without notable immunosuppressive or myelosuppressive effects. Clinically used as its hydrochloride salt, it shows high efficacy in inducing remission in acute leukemia and is also effective against endometrial cancer, hepatocellular carcinoma, gastrointestinal cancers, lung cancer, pancreatic cancer, ovarian cancer, and malignant lymphoma. It is primarily used as an antitumor antibiotic for the treatment of lung cancer, breast cancer, digestive tract cancers, and acute leukemia. |
InChIKey |
USZYSDMBJDPRIF-SVEJIMAYSA-N |